4D Molecular Therapeutics' (FDMT) Sell (E+) Rating Reaffirmed at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT - Free Report) in a research report report published on Saturday morning,Weiss Ratings reports.

Several other equities research analysts also recently issued reports on FDMT. HC Wainwright restated a "buy" rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday, March 3rd. Morgan Stanley decreased their price objective on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an "underweight" rating on the stock in a research note on Monday, January 13th. Chardan Capital lowered their target price on 4D Molecular Therapeutics from $28.00 to $25.00 and set a "buy" rating for the company in a research note on Friday. Bank of America dropped their price objective on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating for the company in a research report on Monday, March 10th. Finally, BMO Capital Markets downgraded 4D Molecular Therapeutics from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $40.00 to $15.00 in a research report on Monday, January 13th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $29.56.

4D Molecular Therapeutics Stock Performance

Shares of FDMT traded up $0.24 during trading hours on Friday, hitting $3.32. 449,993 shares of the company were exchanged, compared to its average volume of 835,043. The company has a market cap of $153.80 million, a PE ratio of -1.16 and a beta of 2.87. The firm's 50 day moving average is $3.37 and its 200-day moving average is $5.22. 4D Molecular Therapeutics has a 52 week low of $2.24 and a 52 week high of $28.93.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.02). As a group, equities analysts forecast that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Barclays PLC grew its stake in 4D Molecular Therapeutics by 141.0% in the third quarter. Barclays PLC now owns 114,848 shares of the company's stock valued at $1,241,000 after acquiring an additional 67,202 shares during the period. Rhumbline Advisers grew its position in shares of 4D Molecular Therapeutics by 5.3% in the 4th quarter. Rhumbline Advisers now owns 73,431 shares of the company's stock valued at $409,000 after purchasing an additional 3,675 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its stake in 4D Molecular Therapeutics by 139.2% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,354 shares of the company's stock worth $364,000 after purchasing an additional 38,031 shares in the last quarter. Proficio Capital Partners LLC raised its holdings in 4D Molecular Therapeutics by 100.0% during the 4th quarter. Proficio Capital Partners LLC now owns 20,000 shares of the company's stock worth $111,000 after buying an additional 10,000 shares during the period. Finally, Vanguard Group Inc. lifted its stake in 4D Molecular Therapeutics by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company's stock valued at $15,933,000 after buying an additional 92,791 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company's stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.